BC Week In Review | Jun 1, 2018
Financial News

Kiniksa upsizes IPO, raises $152.6M

Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) raised $152.6 million on May 23 through the sale of 8.5 million shares at $18 in an upsized IPO underwritten by Goldman Sachs, J.P. Morgan, JMP Securities and Wedbush. Kiniksa priced...
BC Extra | May 24, 2018
Financial News

Kiniksa upsizes IPO, raises $152.6M

Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) gained $1.47 to $19.47 Thursday after raising $152.6 million through the sale of 8.5 million shares at $18 in an upsized IPO underwritten by Goldman Sachs, J.P. Morgan, JMP Securities and...
BC Week In Review | May 4, 2018
Financial News

Ex-Synageva team planning Kiniksa IPO

Kiniksa Pharmaceuticals Ltd. (Hamilton, Bermuda) filed on April 27 to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, J.P. Morgan, JMP Securities and Wedbush PacGrow. Kiniksa Chairman and CEO...
BC Extra | Apr 28, 2018
Financial News

Ex-Synageva team planning Kiniksa IPO

Kiniksa Pharmaceuticals Ltd. (Hamilton, Bermuda) filed to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, J.P. Morgan, JMP Securities and Wedbush PacGrow. Kiniksa Chairman and CEO Sanj Patel, President...
BioCentury | Apr 20, 2018
Finance

Refilling Alexion’s cupboard

The first deal by Alexion Pharmaceuticals Inc.’s freshly rebuilt management team serves to amplify its biggest challenge -- it needs many more external assets to break its Soliris eculizumab dependence, and it may not have...
BC Week In Review | Mar 10, 2017
Company News

Alexion SBC-103 news

Alexion said it will "reduce its investment" in SBC-103 (rhNAGLU). The company said that in 4Q16 it recognized an $85 million impairment charge related to SBC-103. Alexion said no additional trials are planned and that...
BC Extra | Nov 18, 2016
Company News

Management tracks

Diagnostics company Exact Sciences Corp. (NASDAQ:EXAS) promoted Jeff Elliott to CFO from VP of business development and strategy. He replaces the retiring John Bakewell. Neurology company vasopharm GmbH (Wuerzburg, Germany) named Irina Antonijevic CMO, a...
BioCentury | Mar 28, 2016
Strategy

Canbridge can-can

Canbridge Life Sciences Ltd .'s deal with Aveo Pharmaceuticals Inc. will see the Chinese biotech developing its first programs outside Asia. But Chairman and CEO James Xue says the company is not deviating from its...
BioCentury | Nov 9, 2015
Finance

Massive Monday

The BioCentury 100 index posted its biggest one-day gain in more than 15 months when Shire plc (LSE:SHP; NASDAQ:SHPG) announced a $5.9 billion acquisition of Dyax Corp. (NASDAQ:DYAX), but buysiders think other factors contributed to...
BC Extra | Oct 21, 2015
Company News

Management tracks

The U.K.'s BioIndustry Association (BIA) named Jane Osbourn chair of its board, effective January 2016. Osbourn is VP of R&D at the MedImmune LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN). Biosimilars company JHL Biotech Inc....
Items per page:
1 - 10 of 134
BC Week In Review | Jun 1, 2018
Financial News

Kiniksa upsizes IPO, raises $152.6M

Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) raised $152.6 million on May 23 through the sale of 8.5 million shares at $18 in an upsized IPO underwritten by Goldman Sachs, J.P. Morgan, JMP Securities and Wedbush. Kiniksa priced...
BC Extra | May 24, 2018
Financial News

Kiniksa upsizes IPO, raises $152.6M

Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) gained $1.47 to $19.47 Thursday after raising $152.6 million through the sale of 8.5 million shares at $18 in an upsized IPO underwritten by Goldman Sachs, J.P. Morgan, JMP Securities and...
BC Week In Review | May 4, 2018
Financial News

Ex-Synageva team planning Kiniksa IPO

Kiniksa Pharmaceuticals Ltd. (Hamilton, Bermuda) filed on April 27 to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, J.P. Morgan, JMP Securities and Wedbush PacGrow. Kiniksa Chairman and CEO...
BC Extra | Apr 28, 2018
Financial News

Ex-Synageva team planning Kiniksa IPO

Kiniksa Pharmaceuticals Ltd. (Hamilton, Bermuda) filed to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, J.P. Morgan, JMP Securities and Wedbush PacGrow. Kiniksa Chairman and CEO Sanj Patel, President...
BioCentury | Apr 20, 2018
Finance

Refilling Alexion’s cupboard

The first deal by Alexion Pharmaceuticals Inc.’s freshly rebuilt management team serves to amplify its biggest challenge -- it needs many more external assets to break its Soliris eculizumab dependence, and it may not have...
BC Week In Review | Mar 10, 2017
Company News

Alexion SBC-103 news

Alexion said it will "reduce its investment" in SBC-103 (rhNAGLU). The company said that in 4Q16 it recognized an $85 million impairment charge related to SBC-103. Alexion said no additional trials are planned and that...
BC Extra | Nov 18, 2016
Company News

Management tracks

Diagnostics company Exact Sciences Corp. (NASDAQ:EXAS) promoted Jeff Elliott to CFO from VP of business development and strategy. He replaces the retiring John Bakewell. Neurology company vasopharm GmbH (Wuerzburg, Germany) named Irina Antonijevic CMO, a...
BioCentury | Mar 28, 2016
Strategy

Canbridge can-can

Canbridge Life Sciences Ltd .'s deal with Aveo Pharmaceuticals Inc. will see the Chinese biotech developing its first programs outside Asia. But Chairman and CEO James Xue says the company is not deviating from its...
BioCentury | Nov 9, 2015
Finance

Massive Monday

The BioCentury 100 index posted its biggest one-day gain in more than 15 months when Shire plc (LSE:SHP; NASDAQ:SHPG) announced a $5.9 billion acquisition of Dyax Corp. (NASDAQ:DYAX), but buysiders think other factors contributed to...
BC Extra | Oct 21, 2015
Company News

Management tracks

The U.K.'s BioIndustry Association (BIA) named Jane Osbourn chair of its board, effective January 2016. Osbourn is VP of R&D at the MedImmune LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN). Biosimilars company JHL Biotech Inc....
Items per page:
1 - 10 of 134